Physicochemical and biopharmaceutical properties of drug substances and pharmacokinetics

Foye's Principles of Medicinal Chemistry: Seventh Edition

Volumn , Issue , 2013, Pages 61-105

  Jambhekar, Sunil S ^a  

^a LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971282441     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (75)

1. Ariens EJ. Intrinsic activity: partial agonists and partial antagonists. J Cardiovasc Pharmacol 1983;5:S8-S15.
2. Venter JC, Fraser CM. Mechanism of action and regulation. In: Kito S, Segawa T, Kuriyama K, eds. Neurotransmitter Receptors. New York: Plenum Press, 1984.
3. Lefkowitz RJ, Stadel JM, Caron MG. Adenylate cyclase-coupled ß-adrenergic receptors: structure and mechanisms of activation and desensitization. Annu Rev Biochem 1983;52:159-186.
4. Florence AT, Attwood D. Physiochemical Principles of Pharmacy, 2nd Ed. New York: Chapman and Hall, 1988.
5. Wagner JG. Biopharmaceutics and Relevant Pharmacokinetics. Hamilton, IL: The Hamilton Press, 1971.
6. Schanker LS. Absorption of drugs from the rat colon. J Pharmacol Exp Ther 1959;126:283-294.
7. Shore PA, Brodie, BB, Hogben CAM. The gastric of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957;119:361-369.
8. Hogben CAM, Tocco DJ, Brodie BB, et al. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959;125:275-282.
9. Schanker LS. On the mechanism of absorption of drugs from the gastrointestinal tract. J Med Pharm Chem 1960;2;343-359.
10. Schanker LS. Mechanism of drug absorption and distribution. Annu Rev Pharmacol 1961;1:29-44.
11. Schanker LS. Passage of drugs across the gastrointestinal epithelium in drugs and membrane. In: Hogben CAM, ed. Proceedings of the First International Pharmacology Meeting, Vol. 4. New York: McMillan Company, 1963.
12. Schanker LS. Physiological transport of drugs. In: Harper NJ, Simon AB, eds. Advances in Drug Research. London: Academic Press, 1966:71-106.
13. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications, 2nd Ed. Philadelphia: Lea and Febiger, 1989.
14. Schanker LS. Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther 1958;128:81-87.
15. Zimmerman JJ, Feldman S. Physical-chemical properties and biologic activity. In: Foye WO, ed. Principles of Medicinal Chemistry, 3rd Ed. Philadelphia: Lea and Febiger, 1988:7-38.
16. Winne D. The influence of unstirred layers on intestinal absorption in intestinal permeation. In: Kramer M, Lauterbach F, eds. Workshop Conference Hoechest, Vol. 4. Amsterdam: Excerpta Medica, 1977:58-64.
17. Levy G, Leonard JR, Procknal JA. Development of in vitro dissolution tests which correlate quantitatively with dissolution rate limited absorption. J Pharm Sci 1965;54:1319-1325.
18. Kwan KC. Oral bioavailability and first-pass effects. Drug Metab Drug Dispos 1997;25:1329-1336.
19. Burton P, Goodwin J, Vidamas T, et al. Predicting drug absorption: how nature made it a difficult problem. J Pharmacol Exp Ther 2002;303: 889-895.
20. Lipinsky CA, Lombordo F, Dominy W, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25.
21. Stewart B, Wang Y, Surendran N. Ex vivo approaches to predicting oral pharmacokinetics in humans. Ann Repts Med Chem 2000;35:299-307.
22. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-3717.
23. Sinko PJ, Leesman GD, Amidon GL. Predicting fraction of dose absorbed in humans using a macroscopic mass-balance approach. Pharm Res 1991;8:979-988.
24. Avdeef A. Absorption and Drug Development: Solubility, Permeability, and Charge State. New York: Wiley-Interscience, 2003.
25. Artusson P, Karlsson J. Correlation between oral drug absorption in humans and the apparent drug permeability coefficient in human intestinal epithelia (Caco-2) cells. Biochem Biophys Res Commun 1991;14:880-885.
26. Hilgers AR, Smith DP, Biermacher JJ, et al. Predicting oral absorption of drugs: a case study with novel class of antimicrobial agents. Pharm Res 2003;20:1149-1155.
27. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal permeability for passive and carrier- mediated compounds. Pharm Res 1988;5:651-654.
28. Dressman JB, Fleisher D. Mixing-tank model for predicting dissolution rate control oral absorption. J Pharm Sci 1986;75:109-116.
29. Johnson DA, Amidon GL. Determination of intrinsic transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeability. J Theor Biol 1988;131:93-106.
30. Hidalgo I. Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 2001;1:385-401.
31. Fleisher D, Cheng L, Zhou Y, et al. Drug, meal, and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet 1999;36:233-254.
32. Amidon G, Lenncranas H, Shah V, et al. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product and in vivo bioavailability. Pharm Res 1995;12:413-420.
33. Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 2004;5:109-124.
34. Matheney C, Lamb M, Brouwer K, et al. Pharmacokinetics and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001;21:778-796.
35. Foltz EL. Clinical pharmacology of pivampicillin. Antimicrob Agents Chemother 1970;10:442-454.
36. Surendran N, Covits KMY, Han HK, et al. Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT1) transporters for PD 158473, an NMDT antagonist. Pharm Res 1999;16: 391-395.
37. Lin J, Chiba M, Baillie T. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999;51:135-157.
38. Albert A. Chemical aspects of selective toxicity. Nature 1958;182:421-423.
39. Roche EB. Design of Biopharmaceutical Properties through Pro-drugs and Analogs. Washington, DC: American Pharmaceutical Association, 1977.
40. Sinkula AA, Yalkowsky SH. Rationale for design of biologically reversible drug derivatives: pro-drugs. J Pharm Sci 1975;64:181-210.
41. Stella VJ, Charman WN, Naringrekar VH. Prodrugs. Do they have advantages in clinical practice? Drugs 1985;29:455-473.
42. Stella V. Pro-drugs: an overview and definition. In: Higuchi T, Stella V, eds. Pro-drugs as Novel Drug Delivery Systems. ACS Symposium Series. Washington, DC: American Chemical Society, 1975:1-115.
43. Beaumont K, Webster R, Gardner I, et al. Design of ester pro-drugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 2003;4:461-485.
44. Noyes NA, Whitney WR. The rate of solution of solid substances in their own solution. J Am Chem Soc 1897;19:930-942.
45. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics, 4th Ed. Philadelphia: Lea and Febiger, 1991.
46. Ogata H, Shibazoki T, Inoue T, et al. Studies on dissolution tests of solid dosage forms. IV. Relation of absorption sites of sulfonamides administered orally in solid dosage forms to their solubilities and dissolution rates. Chem Pharm Bull 1979;27:1281-1286.
47. Pottage A, Nimmo J, Prescott LF. The absorption of aspirin and paracetamol in patients with achlorhydria. J Pharm Pharmacol 1974;26:144-145.
48. Juncher H, Raaschou F. Solubility of oral preparation of penicillin V. Antibiotic Med 1957;4:497-507.
49. Anderson KW. Oral absorption of quinalbarbitone and its sodium salt. Arch Int Pharmacodyn Ther 1964;147:171-177.
50. Grant DJW. Theory and origin of polymorphism. In: Brittain HG, ed. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker, 1999:1-34.
51. Brittain HG, Grant DJW. Effect of polymorphism and solid-state solvation on solubility and dissolution rate. In: Brittain HG, ed. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker, 1999:34-66.
52. Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in drug absorption. Pharm Res 1996;13:1795-1798.
53. Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci 1985;74:588-589.
54. Lombardo F, Obach RS, Dicapua FM, et al. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J Med Chem. 2006;49:2262-2267.
55. Lombardo F, Obach RS, Shalaeva MY, et al. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002;45:2867-2876.
56. Lombardo F, Obach RS, Shalaeva MY, et al. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leaveclass- out statistics. J Med Chem 2004;47:1242-1250.
57. Ehrnebo M, Boreus L, Lonroth U. Bioavailability and first-pass metabolism of oral pentazocine in man. Clin Pharmacol Ther 1977;22:888-892.
58. Notari R. Pharmacokinetics and molecular modification: implications in drug design and evaluation. J Pharm Sci 1973;62:865-881.
59. Avdeef A. Absorption and Drug Development: Solubility, Permeability, and Charge State. New York: Wiley-Interscience, 2003.
60. Florence A, Siepman J, eds. Modern Pharmaceutics, 5th Ed. New York: Informa Healthcare, 2009.
61. Ganellin C, Roberts S, eds. Medicinal Chemistry: The Role of Organic Chemistry in Drug Research, 2nd Ed. New York: Academic Press, 1993.
62. Garrett E. Classical pharmacokinetics to frontiers. J Pharmacokinet Biopharm 1973;1:341-361.
63. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics, 4th Ed. Philadelphia: Lea and Febiger, 1991.
64. Gibaldi M, Perrier D. Pharmacokinetics, 2nd Ed., Vol. 15: Drugs and the Pharmaceutical Sciences. New York: Marcel Dekker, 1982.
65. Hilfiker R, ed. Polymorphism. Weinheim, Germany: Wiley-VCH Verlag, 2006.
66. Horter D, Dressman JB. Influence of physiochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001;46:75-87.
67. Hug C. Pharmacokinetics of drugs administered intravenously. Anesth Analg 1978;57:704-723.
68. Jambhekar S, Breen P. Basic Pharmacokinetics, 1st Ed. London: Pharmaceutical Press, 2009.
69. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Application, 3rd Ed. Philadelphia: Lea and Febiger, 1994.
70. Steffansen B, Brodin B, Nielsen U, eds. Molecular Biopharmaceutics. London: Pharmaceutical Press, 2010.
71. Taylor J, Kennewell P. Modern Medicinal Chemistry: Ellis Horwood Series in Pharmaceutical Technology. New York: Ellis Horwood, 1993.
72. Wagner J. A modern view of pharmacokinetics. J Pharmacokinet Biopharm 1973;1:363-401.
73. Wagner J. Do you need a pharmacokinetic model, and, if so, which one? J Pharmacokinet Biopharm 1975;3:457-478.
74. Welling P. Pharmacokinetics: Processes and Mathematics. Monograph 185. Washington, DC: American Chemical Society, 1986.
75. Wermuth C, Koga N, Konig H, et al. Medicinal Chemistry for the 21st Century. Boston: Blackwell Scientific Publications, 1992.